Cargando…
Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for thes...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912698/ https://www.ncbi.nlm.nih.gov/pubmed/31683817 http://dx.doi.org/10.3390/jcm8111819 |
_version_ | 1783479518382522368 |
---|---|
author | Abuhasira, Ran Ron, Addie Sikorin, Inbal Novack, Victor |
author_facet | Abuhasira, Ran Ron, Addie Sikorin, Inbal Novack, Victor |
author_sort | Abuhasira, Ran |
collection | PubMed |
description | Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events. |
format | Online Article Text |
id | pubmed-6912698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69126982020-01-02 Medical Cannabis for Older Patients—Treatment Protocol and Initial Results Abuhasira, Ran Ron, Addie Sikorin, Inbal Novack, Victor J Clin Med Article Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events. MDPI 2019-11-01 /pmc/articles/PMC6912698/ /pubmed/31683817 http://dx.doi.org/10.3390/jcm8111819 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Abuhasira, Ran Ron, Addie Sikorin, Inbal Novack, Victor Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title | Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title_full | Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title_fullStr | Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title_full_unstemmed | Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title_short | Medical Cannabis for Older Patients—Treatment Protocol and Initial Results |
title_sort | medical cannabis for older patients—treatment protocol and initial results |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912698/ https://www.ncbi.nlm.nih.gov/pubmed/31683817 http://dx.doi.org/10.3390/jcm8111819 |
work_keys_str_mv | AT abuhasiraran medicalcannabisforolderpatientstreatmentprotocolandinitialresults AT ronaddie medicalcannabisforolderpatientstreatmentprotocolandinitialresults AT sikorininbal medicalcannabisforolderpatientstreatmentprotocolandinitialresults AT novackvictor medicalcannabisforolderpatientstreatmentprotocolandinitialresults |